single10MG
Mazdutide
10MG Protocol
Mazdutide 10MG
Injection Freq.
Inject once weekly
Cycle Sched.
Minimum 8 weeks; clinical evidence supports 12–48 week protocols
Reconstitution
3.0 mL BAC water
Significant body-weight reduction reported in obesity trials
HbA1c improvement reported in type 2 diabetes populations
Favorable metabolic effects (lipids and glucose control described)
Once-weekly dosing convenience may improve adherence
1
Reconstitution Requirements
- 3.0 mL BAC water
Escalation steps: 2
Defined through week 5
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 2.5 mg (2,500 mcg) | 75 |
| 2 | Weeks 5+ | 5 mg (5,000 mcg) | 150 |
Inject once weekly
Minimum 8 weeks; clinical evidence supports 12–48 week protocols
Mazdutide is characterized as a dual agonist at both GLP-1 and glucagon receptors. The protocol frames its mechanism as combining two complementary metabolic signals: GLP-1 receptor activation supports appetite suppression and improved glucose control, while glucagon receptor activation contributes to increased energy expenditure. This dual-pathway design is presented as a key distinction from single-target GLP-1 agonists, potentially supporting greater weight-loss efficacy by pairing reduced energy intake with higher caloric burn. The page summarizes clinical-trial observations in which weekly administration produced meaningful reductions in body weight over multi-month periods and improved glycemic markers (including HbA1c) in type 2 diabetes populations. Mechanistically, the extended half-life is emphasized as enabling once-weekly dosing with steady pharmacologic exposure, which supports consistent receptor engagement and may improve adherence in research/clinical protocols.
Nausea
Vomiting
Diarrhea
Constipation
Injection-site reactions (redness/swelling/discomfort)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)